Lytix Biopharma AS Cash Flow Conversion Efficiency
Lytix Biopharma AS cash flow conversion efficiency. Based on the latest financial reports, Lytix Biopharma AS (LYTIX) has a cash flow conversion efficiency ratio of -0.969x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-59.85 Million ≈ $-6.30 Million USD) by net assets (Nkr61.75 Million ≈ $6.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lytix Biopharma AS (2017–2025)
Cash flow conversion efficiency of Lytix Biopharma AS from 2017 to 2025. This chart illustrates how Lytix Biopharma AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Lytix Biopharma AS stock price today for real-time trading data and today's change.
Lytix Biopharma AS Cash Flow Conversion Ratio Explained
Lytix Biopharma AS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lytix Biopharma AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lytix Biopharma AS ranked by their cash flow conversion efficiency. Also see LYTIX company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Showbox Corp
KQ:086980
|
0.346x |
|
Aker Technology Co Ltd
TWO:6174
|
-0.004x |
|
Northview Acquisition Corp
NASDAQ:NVAC
|
0.029x |
|
Panin Sekuritas Tbk
JK:PANS
|
0.079x |
|
LumenRadio AB
ST:LUMEN
|
0.037x |
|
Abionyx Pharma SA
PA:ABNX
|
-0.314x |
|
TV Today Network Limited
NSE:TVTODAY
|
-0.051x |
|
Milestone Pharmaceuticals Inc
NASDAQ:MIST
|
-0.479x |
Annual Cash Flow Conversion Efficiency for Lytix Biopharma AS (2017–2025)
The table below shows the annual cash flow conversion efficiency of Lytix Biopharma AS from 2017 to 2025. Review Lytix Biopharma AS free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr61.75 Million ≈ $6.50 Million |
Nkr-59.85 Million ≈ $-6.30 Million |
-0.969x | -48.60% |
| 2024-12-31 | Nkr107.89 Million ≈ $11.35 Million |
Nkr-70.37 Million ≈ $-7.41 Million |
-0.652x | +65.12% |
| 2023-12-31 | Nkr51.32 Million ≈ $5.40 Million |
Nkr-95.97 Million ≈ $-10.10 Million |
-1.870x | -385.00% |
| 2022-12-31 | Nkr135.13 Million ≈ $14.22 Million |
Nkr-52.10 Million ≈ $-5.48 Million |
-0.386x | -62.86% |
| 2021-12-31 | Nkr189.62 Million ≈ $19.95 Million |
Nkr-44.90 Million ≈ $-4.72 Million |
-0.237x | +80.66% |
| 2020-12-31 | Nkr19.89 Million ≈ $2.09 Million |
Nkr-24.35 Million ≈ $-2.56 Million |
-1.224x | +54.85% |
| 2019-12-31 | Nkr13.58 Million ≈ $1.43 Million |
Nkr-36.82 Million ≈ $-3.87 Million |
-2.711x | -53.27% |
| 2018-12-31 | Nkr41.05 Million ≈ $4.32 Million |
Nkr-72.62 Million ≈ $-7.64 Million |
-1.769x | +70.06% |
| 2017-12-31 | Nkr11.79 Million ≈ $1.24 Million |
Nkr-69.67 Million ≈ $-7.33 Million |
-5.909x | -- |
About Lytix Biopharma AS
Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic… Read more